How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Medicinal Amber Glass Vial Market
- By Volume Capacity: 1 mL, 2 mL, 5 mL, 10 mL, 20 mL
- By Closure Type: Screw Cap, Crimp Cap, Snap Cap, Flip-Off Cap
- By Sterilization Method: Gamma Sterilized, Autoclave Sterilized, Ethylene Oxide Sterilized, Non-Sterile
- By Application: Injectable Drugs, Vaccines, Biologics, Diagnostic Reagents, Cosmeceuticals
- By Glass Type: Borosilicate Glass, Soda Lime Glass
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - 1 mL leads By Volume Capacity at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 293 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.177 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.185 →
Full report · locked preview
Everything inside the Medicinal Amber Glass Vial Market report
A complete, evidence-based study - 12 chapters and 123 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Volume Capacity 5
Closure Type 4
Sterilization Method 4
Application 5
Glass Type 2
Companies profiled
SCHOTT AG
Gerresheimer AG
Nipro Corporation
O.Berk Company
West Pharmaceutical Services Inc.
Stevanato Group
AptarGroup Inc.
SGD Pharma
Nexeo Solutions
All Glass International
Vetter Pharma International GmbH
Corning Incorporated
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →SCHOTT AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Gerresheimer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Nipro Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →O.Berk Company
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →West Pharmaceutical Services Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Stevanato Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →AptarGroup Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →SGD Pharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Nexeo Solutions
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →All Glass International
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Vetter Pharma International GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Corning Incorporated
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Amcor plc
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Berry Global Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →MJS Packaging
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$11,984M by 2033 · 10.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- 1 mL41.9
- 2 mL19.2
- 5 mL18.3
- 10 mL10.8
- 20 mL9.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,737M → $4,434M · 12.4%
Europe$1,211M → $2,983M · 11.9%
Asia Pacific$1,106M → $2,761M · 12.1%
Latin America$684.4M → $1,462M · 10.0%
Middle East and Africa$526.5M → $1,134M · 10.1%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.782026
10.792027
10.802028
10.822029
10.822030
10.842031
10.862032
10.872033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- SCHOTT AG19.7
- Gerresheimer AG18.7
- Nipro Corporation9.2
- O.Berk Company7.7
- West Pharmaceutical Services Inc.8.7
- Stevanato Group8.1
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Volume Capacity18.2%
Closure Type28.1%
Sterilization Method27.7%
Application8.5%
Glass Type17.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe23.4
- Asia Pacific21.6
- Latin America11.4
- Middle East and Africa8.9
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| SCHOTT AG | 91 | 87 | 84 | 80 | 89 | 82 | 86 |
| Gerresheimer AG | 70 | 69 | 93 | 87 | 81 | 91 | 82 |
| Nipro Corporation | 64 | 76 | 70 | 66 | 72 | 71 | 70 |
| O.Berk Company | 72 | 77 | 62 | 57 | 76 | 75 | 70 |
| West Pharmaceutical Services Inc. | 73 | 60 | 55 | 62 | 59 | 58 | 61 |
| Stevanato Group | 56 | 51 | 70 | 57 | 70 | 65 | 62 |
| AptarGroup Inc. | 64 | 60 | 55 | 56 | 54 | 55 | 57 |
| SGD Pharma | 40 | 49 | 44 | 39 | 38 | 45 | 43 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- SCHOTT AG
- Gerresheimer AG
- Nipro Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| SCHOTT AG | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Gerresheimer AG | ✓ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Nipro Corporation | ◐ | ◐ | − | ◐ | ◐ | ✓ |
| O.Berk Company | ◐ | ✓ | ◐ | − | ◐ | ◐ |
| West Pharmaceutical Services Inc. | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Stevanato Group | − | − | − | − | ◐ | − |
| AptarGroup Inc. | − | ◐ | ◐ | ◐ | − | ◐ |
| SGD Pharma | ◐ | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1SCHOTT AG86
2Gerresheimer AG82
3Nipro Corporation70
4O.Berk Company70
5Stevanato Group62
6West Pharmaceutical Services Inc.61
7AptarGroup Inc.57
8SGD Pharma43
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
SCHOTT AGGerresheimer AG
Challenger2
Strong scale, closing on the leaders.
Nipro CorporationO.Berk Company
Contender3
Focused players with pockets of strength.
West Pharmaceutical Services Inc.Stevanato GroupAptarGroup Inc.
Niche1
Specialists in a single segment or region.
SGD Pharma
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Volume Capacity in North America, then scale across Medicinal Amber Glass Vial Market — a $281M beachhead inside a $4.58B market.
Beachhead (SOM)$281Mobtainable near-term
Serviceable (SAM)$1.92Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
1 mL
Best fit — highest urgency & budget in Volume Capacity.
Economic buyer79 fit
2 mL
Strong fit — clear ROI and a fast path to value.
End user68 fit
5 mL
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Volume Capacity in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Closure Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Sterilization Method
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel29%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Volume Capacity leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Medicinal Amber Glass Vial Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified24%
Evaluation12%
Closed-won5%
$15.8KCAC
$73KLTV
4.6:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Medicinal Amber Glass Vial Market is a resilient opportunity — $4.04B by 2033, compounding at 3.9%.
TAM · 2025$2.98Btoday
TAM · 2033$4.04Bforecast
CAGR3.9%2027–2033
Cumulative$31.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.04BTotal addressable market
SAM$1.61BServiceable available market
SOM$294MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →3.9% CAGR
Demand compounds through 2033, outpacing GDP across Volume Capacity.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Volume Capacity moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.04BLarge & growingTAM by 2033 at 3.9% CAGR
$1.61BServiceable nowreachable with today’s model
$294MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.15BBear2.5% CAGR
$4.04BBase3.9% CAGR
$5.17BBull5.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Closure Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Medicinal Amber Glass Vial Market — a $7.57B market by 2033. Plan: grow share from 7.4% to 13.5%.
Market size · 2033$7.57Btotal addressable
Market CAGR9.4%2027–2033
Target share13.5%from 7.4% today
Revenue ambition$1.02Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.4% | 13.5% | At risk |
| Revenue | $589M | $1.02B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 30.1% | 40.5% | At risk |
| Customer retention | 86.7% | 95.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Volume Capacity
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Closure Type capability
A defensible second engine — invest in Closure Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Volume Capacity share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Closure Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $144M capacity & capability investment
- Greenlight bolt-on M&A in Closure Type
- Authorise North America expansion plan
- Fund R&D program for Volume Capacity leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAt risk
- Input-cost & supply riskAhead
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Medicinal Amber Glass Vial Market conversation — a $2.63B market you can size, segment and defend in minutes.
Market size · 2033$2.63Btotal opportunity
Growth8.1%CAGR to 2033
Addressable buyers1,206+accounts in scope
Typical ROI6.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Volume Capacity
Goal Grow share in Volume Capacity
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.4×return on cost, year one
< 4 mopayback period
$94K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
SCHOTT AGGerresheimer AGNipro CorporationO.Berk CompanyWest Pharmaceutical Services Inc.Stevanato GroupAptarGroup Inc.SGD Pharma+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Medicinal Amber Glass Vial Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Medicinal Amber Glass Vial Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Medicinal Air Plants Market
Market size, share, segmentation and regional forecast.
$421M market · 2025 base year
View reportMediceal Drains Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportMedication Trolley Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportMedication Tracking Software Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportMedication Therapy Management (MTM) Services Market
Market size, share, segmentation and regional forecast.
$2.1B market · 2025 base year
View reportMedication Therapy Management Market
Market size, share, segmentation and regional forecast.
$751M market · 2025 base year
View reportMedications Used in Acne Treatment Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportMedications for Treating Alcohol Dependence Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportMedications for Prurigo Nodularis Market
Market size, share, segmentation and regional forecast.
$5.5B market · 2025 base year
View reportMedications for Meibomian Gland Dysfunction Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportMedications for Heart Failure Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportMedications for Fibromyalgia Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.